| Revenue growth | 43% YoY in Q1FY27; 32% YoY in FY26. |
|---|---|
| Margins | Q1FY27 EBITDA margin at 19% vs 15% YoY. |
| Demand visibility | Recurring demand for PTC; SDA demand driven by emission norms. |
Growth
Revenue up 43% YoY; EBITDA increased 86% YoY to ₹323 Mn; PAT surged 140% YoY to ₹160 Mn.
Outlook
Capex planned to boost capacities. Focused on niche specialty chemicals and expanding SDA/PASC segments.
Risks
High industry barriers with 1-6 year product approval cycles; potential geopolitical shifts impacting exports (75% of revenue).
Last quarter's promises, checked
Delivered
- Guided 25% revenue growth → delivered 43% YoY (= BEAT)
- Guided 20-22% EBITDA margin → delivered 19% (= PARTIAL)
- Guided SDA growth 20%+ → delivered SDA as primary driver (= BEAT)
Partly delivered
- Guided INR 100 Cr FY27 Capex → Ongoing capacity expansion (= PARTIAL)
Earnings Call filed with NSE, NSE: TATVA. Summary written with AI assistance from the document.
Tatva Chintan Pharma Chem Ltd: key numbers
- Share price
- ₹1,991.20
- Market cap
- ₹4,658 Cr
- Revenue (annual)
- ₹505.9 Cr
- Net profit (annual)
- ₹42.05 Cr
- P/E (TTM)
- 90.7×Sector 36.8×
- Promoter holding
- 72.02%+0.00% QoQ
- FII holding
- 3.93%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Tatva Chintan Pharma Chem Ltd
All →Tatva Chintan Pharma Chem Annual General Meeting
The company held its 30th Annual General Meeting on September 25, 2026. Shareholders considered and approved items including financial statements and director re-appointments.
Tatva Chintan Pharma Chem Credit Rating
CRISIL Ratings upgraded Tatva Chintan's long-term bank facilities to CRISIL A-/Stable and short-term facilities to CRISIL A2+. This upgrade reflects the company's improved credit profile.
Tatva Chintan Pharma Chem Business Update
Tatva Chintan Pharma Chem Limited submitted its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26. The report highlights its specialty chemicals operations and ESG metrics.
Tatva Chintan Pharma Chem Annual Report
Tatva Chintan Pharma Chem Limited has submitted its Annual Report for the financial year 2025-26. The company's 30th Annual General Meeting is scheduled for September 25, 2026.
Tatva Chintan Pharma Chem Annual General Meeting
Tatva Chintan Pharma Chem Limited has scheduled its 30th Annual General Meeting for September 25, 2026. Key agenda items include dividend declaration and director re-appointments.
Tatva Chintan Pharma Chem Annual General Meeting
Tatva Chintan Pharma Chem Limited scheduled its 30th AGM for September 25, 2026. Key agenda items include dividend declaration and increasing borrowing limits to ₹1,000 Crore.
- Value
- ₹1,000 Cr